Search Results 1281-1290 of 18745 for Relapse
NL-201 in Patients With Relapsed or Refractory Cancer. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to ...
Also, to improve disease control by decreasing the number of spinal relapses ... Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with ...
The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...
Root Cause of Multiple Myeloma Relapse Revealed. Dana Sparks. September 18, 2013. Mayo Clinic Receives $8.8 Million Federal Grant for Metabolomics Center.
Treatment-naïve or relapsed/refractory CLL patients undergoing CLL antineoplastic treatment. Diagnosis of B-cell CLL established according to International ...
Stephen Erickson, every couple of months just to make sure nothing is going to relapse, but I feel great right now," Kelli says. She gives much of the ...
The primary purpose of this study is to compare 1 year graft-versus-host disease (GVHD)-free, graft relapse-free survival (GRFS) between the two GVHD ...
Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin ...
However, the response to PARP inhibitors is much more limited when ovarian cancer has relapsed during PARP inhibitor treatment or when the cancer lacks HR ...
Latest stories. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.